Nurix Therapeutics (NRIX) said Monday that the US Food and Drug Administration has granted orphan drug designation to the company's experimental drug, bexobrutideq, for treating Waldenstrom macroglobulinemia, a type of blood cancer.
The company said the drug is currently being evaluated in a phase 1 trial for adults with relapsed or refractory B-cell malignancies.
The US health agency's orphan drug designation program supports the development of treatments for rare diseases, impacting fewer than 200,000 individuals in the US, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。